Jasper Therapeutics, Inc. Logo

Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):
US4718712023 (+3 more)
LEI:
Country:
United States of America
Address:
2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America MDXG
Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America MNMD
Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America MLYS
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America MIRA
Mirum Pharmaceuticals, Inc. Logo
Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.
United States of America MIRM
Mithra Pharmaceuticals S.A. Logo
Biotech firm developing pharma for women's health: contraception, fertility, and menopause.
Belgium MITRA
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan 4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea 142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden MOB

Talk to a Data Expert

Have a question? We'll get back to you promptly.